Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/pbc.23319 http://scihub22266oqcxt.onion/10.1002/pbc.23319 C4504194!4504194!21922647     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pediatr+Blood+Cancer 2012 ; 59 (2): 329-32 Nephropedia Template TP {{tp|p=21922647|t=2012. Initial Testing of JNJ-26854165 (Serdemetan) by the Pediatric Preclinical Testing Program |pdf=|usr=}}{{21922647}} gab.com Text Initial Testing of JNJ-26854165 (Serdemetan) by the Pediatric Preclinical Testing Program JO: Pediatr Blood Cancer http://www.kidney.de/pget.php?&tw=1&pmid=21922647 #FOAvip JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC50 (0.85 µM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53. Twit Text FOAVip Initial Testing of JNJ-26854165 (Serdemetan) by the Pediatric Preclinical Testing Program ????Pediatr Blood Cancer http://www.kidney.de/pget.php?&tw=1&pmid=21922647 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=21922647 #FOAvip English Wikipedia <ref>{{Cite pmid|21922647}}</ref> Initial Testing of JNJ-26854165 (Serdemetan) by the Pediatric Preclinical Testing Program #MMPMID21922647 Smith MA; Gorlick R; Kolb EA; Lock R; Carol H; Maris JM; Keir ST; Morton CL; Reynolds CP; Kang MH; Arts J; Bashir T; Janicot M; Kurmasheva RT; Houghton PJ Pediatr Blood Cancer 2012[Aug]; 59 (2): 329-32 PMID21922647show ga JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC50 (0.85 µM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53. äInitial Testing of JNJ-26854165 (Serdemetan) by the Pediatric Preclini(epmc).pdf DeepDyve Pubget Overpricing